mdlinx mdlinx
Latest (24) Full Text Articles (547) Article Summary

Shareholders are investing 8.3 million Euro in the expanding business–Rainer Hepberger new CFO–Phase III study begins for ICES13
B3C newswire,

In order to continue on its agreed expansion course, the Austrian biotechnology company Innovacell is acquiring fresh capital: shareholders in the firm, which is developing cell–therapy for the treatment of stress–urinary incontinence (ICES13) and faecal incontinence, have agreed on a capital expansion of 8.3 million Euro. This will take effect in two tranches. The main shareholders are the financial investors Buschier, Fides, HYBAG und the private equity firm, uni venture.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

Last month's top read Top Articles of 2013

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Other Topics in Pharma News

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register
Upcoming Clinical Trials UPCOMING Clinical Trials

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close